Erythromycin in neonatal postoperative intestinal dysmotility

Area of Science:

• Pediatric Gastroenterology
• Pharmacology
• Surgical Outcomes

Background:

• Severe intestinal dysmotility poses significant challenges in infants, often requiring prolonged parenteral nutrition.
• Gastrointestinal surgery can exacerbate intestinal motility issues, leading to prolonged recovery periods.
• Neuropathic intestinal pseudo-obstruction and intestinal myopathy are distinct conditions affecting gut motility.

Purpose of the Study:

• To evaluate the efficacy of erythromycin, a motilin agonist, in infants with severe intestinal dysmotility.
• To assess the response to erythromycin in specific pediatric gastrointestinal motility disorders.
• To determine if erythromycin is effective in managing post-surgical intestinal dysmotility and other motility conditions.

Main Methods:

• Retrospective case series analysis of infants treated with erythromycin.
• Inclusion of patients with severe intestinal dysmotility post-gastrointestinal surgery.
• Inclusion of patients with neuropathic intestinal pseudo-obstruction and intestinal myopathy.

Main Results:

• Erythromycin was successfully used in four infants with severe intestinal dysmotility following gastrointestinal surgery, enabling prolonged parenteral nutrition.
• A significant small intestinal manometric response to erythromycin was observed in one child with neuropathic intestinal pseudo-obstruction.
• Erythromycin demonstrated no therapeutic effect in a child diagnosed with intestinal myopathy.

Conclusions:

• Erythromycin is a potential therapeutic option for severe intestinal dysmotility in infants, particularly those with post-surgical complications.
• The motilin agonist erythromycin shows differential efficacy, being effective in certain motility disorders but not others.
• Further research is warranted to elucidate the role of erythromycin in managing pediatric gastrointestinal motility disorders.